ingredient Trelagliptin 100mg
substitutes Trelagliptin 100mg
treatment Type 2 diabetes mellitus
Shipping class Room Temperature
Medicine Overview by Anukar Pharmacy
( Wedica 100mg 16 Tablet, Beacon )
TreatmentIndicated for Type 2 diabetes mellitus, When the first line treatment of Metformin is not achieving the expected Glycemic goals.
Side EffectsHypoglycemia, nasopharyngitis, and elevated lipase.
Method of UseThis medication is to be taken once weekly, and on the same day every week.
How Wedica 100mg 16 Tablet, Beacon WorksBy inhibiting the activity of dipeptidyl peptidase 4 Trelagliptin inactivates glucagon-like peptide 1 (GLP-1) from secretion from the intestines to the blood via stimulation from oral intake of food, increases GLP-1 blood concentration and promotes blood glucose concentration-dependent insulin secretion from the pancreas. Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It works to raise the concentration of glucose in the bloodstream. Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. They also inhibit glucagon release from the alpha cells of the islets of Langerhans. DPP-4 plays a major role in glucose metabolism. It is responsible for the degradation of incretins and increase blood glucose level.
More Info by Anukar Pharmacy
( Wedica 100mg 16 Tablet, Beacon )
Suggestions
- This drug may cause hypoglycemia when used in combination with other diabetes medications, so thoroughly explain and caution the patient of such risks of hyoglycemia when combining with other medications. There is an increased risk of hypoglycemia particularly when combined with sulfonylurea drugs and insulin medications. Consider reducing the dose of sulfonylurea drugs or insulin medication when used in combination with these drugs in order to lessen the risk of hypoglycemia.
- This drug is to be taken orally once per week. Effects may persist even after dosage is ceased, so take sufficient notice of blood sugar values and side effects. Moreover, evaluate the starting period and dose based on the state of blood sugar management when using other diabetes medications after cessation of this medication.
- Only consider application for patients with established diagnosis of diabetes mellitus. Pay attention to conditions that show abnormal sugar resistance, glucosurea, and other symptoms resembling diabetes (renal glucosuriea, thyroid function abnormality, etc.)
- Application of this drug should only be considered once diet- and exercise-based diabetes treatments have already been implemented with unsatisfactory results.
- During administration of this drug, progress should be sufficiently observed along with quantitative blood sugar measurements. If no results are seen after 2 to 3 months of treatment, consider changing to a more appropriate treatment method.
- During dosage maintenance, the medication may no longer become necessary, or the effects of the drug may diminish due to complications with poor nutrition or infectious disease. In such cases, evaluate continuation of normal does, medication selection, etc. upon consideration of dietary volume, blood sugar levels, and presence of infectious symptoms.
- Warn patients that work in high places, operate machinery, etc., as low blood sugar can occur.
- Clinical results and safety regarding combination with insulin medication has not been investigated.
- This drug and GLP-1 receptor agonists both possess the ability to lower blood sugar and assist GLP-1 receptor agonists.There are no clinical study results regarding the combination of these medications, and neither the efficacy nor the safety can be confirmed
Warning by Anukar Pharmacy
( Wedica 100mg 16 Tablet, Beacon )
Special precautions for Wedica 100mg 16 Tablet, Beacon Heads up
| aspect | highlight | details |
|---|---|---|
Alcohol
|
caution | Patients consuming alcohol must take with caution.Patients consuming alcohol must take with caution. |
Pregnancy
|
No significant interactions found | |
Lactation
|
No significant interactions found | |
Driving
|
No significant interactions found. | |
Kidney
|
caution | For patients with moderate kidney function disease, the blood level have to be monitored. |
Liver
|
caution | For patients with moderate kidney function disease, the blood level have to be monitored.For patients with moderate kidney function disease, the blood level have to be monitored. |
Suggestion by Anukar Pharmacy on missing a dose
( Wedica 100mg 16 Tablet, Beacon )
If patient forgets to take medication as scheduled, only take the quantity intended for the time in which the forgotten dose was realized, and then continue dosage according to a newly decided schedule afterwards.
Disclaimer
The information of Anukar Pharmacy is for reference purpose only, and Anukar Pharmacy or Anukar Pharmacy or Anukar Pharmacy is not intended to be a replacement of professional medical advice, diagnosis, or treatment. Anukar Pharmacy suggest to ask the advice of a physician or any qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of anything you have learned from Anukar Pharmacy.
| 药名 | 曲格列汀, 琥珀酸曲格列汀 |
| 厂家 | 碧康制药 |
| 成分 | 二肽基肽酶IV（DPP-4）抑制剂 |
| 说明 |
曲格列汀
曲格列汀 商品名称：Zafatek 全部名称：曲格列汀,Zafatek,Wedica
适用于2型糖尿病
|
* 以上中文信息由印度阿努卡药房收集的Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）中文网络信息和软件翻译获得，阿努卡药房认为Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）中文产品介绍信息存在与Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）实际数据不一致的可能。阿努卡药房请用户把Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）页面数据作为参考。印度阿努卡药房建议用户在实际使用Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）数据或者信息时，以Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）制造商公开发布的Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）商品信息为参考。使用方法，以用户医生建议使用Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）决定为参考。用户任何关于Wedica 100mg 16 Tablet, Beacon（曲格列汀, 琥珀酸曲格列汀）的建议，可以通知印度阿努卡药房，或通知阿努卡在线客服人员。谢谢
